• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>PIMCO Municipal Income II

PIMCO Municipal Income II

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment

    TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment

  2. Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis

    Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis

  3. A Closer Look at CEF Duration Risk

    An examination of 10 CEFs with the highest duration risk.

  4. Year in Review: Municipal CEFs

    We take a look at 2012's municipal CEF performance, distribution cuts, mergers, and more.

  5. FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers

    FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers

©2017 Morningstar Advisor. All right reserved.